Compare Invitation Homes Inc. Common Stock (INVH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Zoetis Inc — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.68B), while Zoetis Inc trades at $75.72 (market cap $31.11B). The key difference: Zoetis Inc is the larger of the two by market cap, and Invitation Homes Inc. Common Stock pays the higher dividend (4.52%). Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| INVH | ZTS | |
|---|---|---|
Market Cap | $15.68B | $31.11B |
Volume | 3,619,685 | 2,515,954 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $147.53 |
52-Week Low | $24.39 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $24.13B | $38.68B |
Dividend Yield | 4.52% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.
ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
